JAMA Neurol: Beware of inflammatory CNS event risk caused by TNF inhibitor therapy

Tumor necrosis factor (TNF) inhibitors are commonly used drugs to treat certain autoimmune diseases, such as rheumatoid arthritisRecently, researchers examined the relationship between the use of tumor necrosis inhibitors and inflammatory central nervous system (CNS) eventsresearchers collected cases of autoimmune disease patients at the Mayo Clinic from January 1, 2003 to February 20, 2019, who received Fda-approved TNF inhibitors for the treatment of autoimmune diseases, including rheumatoid arthritis, strong scoliosis, psoriasis, psoriasis arthritis, Crohn's disease, and ulcerative colitisRecord patient TNF inhibitor exposure, type, and cumulative exposure timeThe main results of the study were inflammatory demyelinator (multiple sclerosis and other diseases, such as optic neuritis) or non-myelin (meningitis, meningoencephalitis, encephalitis, neuroconycosis and CNS vasculitis) CNS eventsa total of 212 patients participated in the study, of which 106 had an inflammatory CNS event and 106 in the control group, of which 136 (64%) were women with an average age of 52 yearsExposure to TNF inhibitors in 64 patients (60%) and 42 control groups (40%) was associated with an increased risk of any inflammatory CNS event (correction OR: 3.01)When the results are layered by demyelinator and non-demyelination CNS events, the results are similarThe second analysis found that the correlation between rheumatoid arthritis patients (corrected OR:4.82) was most significantstudies have found that patients with autoimmune diseases who receive TNF inhibitors are at increased risk of inflammatory CNS events